Dossier assessment
Finerenone (heart failure with LVEF ≥ 40%) – Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Finerenone (heart failure with LVEF ≥ 40%) – Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Finerenone (heart failure with LVEF ≥ 40%) – Benefit assessment according to §35a Social Code Book V
Drug assessment at a glance
-
Drug assessment at a glance
Finerenone (heart failure with LVEF ≥ 40%) – Benefit assessment according to §35a Social Code Book V
Dossier assessment
Adults with symptomatic chronic heart failure with left ventricular ejection fraction ≥ 40%
Added benefit not proven
Additional information
Federal Joint Committee (GBA)
15-10-2026 A G-BA decision was published.
GBA documents on this decision
Project details
- Project no.
- A26-42
- Commission
- Commission awarded on 22.04.2026 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Heart and circulation
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
- DOI
https://doi.org/10.60584/A26-42
Connected Projects
-
Dossier assessment
Finerenone (CKD stage 1 and 2) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Finerenone (CKD stage 2 and 3) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Addendum
Finerenone (heart failure with LVEF ≥ 40%) – Addendum to Project A26-42
Status: Commission completed